Literature DB >> 34395759

Long-term in vitro Culture of Cryptosporidium parvum.

Nigel Yarlett1,2, Mary Morada1.   

Abstract

Continuous in vitro growth of Cryptosporidium parvum has proved difficult and conventional in vitro culture techniques result in short-term (2-5 days) growth of the parasite resulting in thin-walled oocysts that fail to propagate using in vitro cultures, and do not produce an active infection using immunosuppressed or immunodeficient mouse models (Arrowood, 2002). Here we describe the use of hollow fiber bioreactors (HFB) that simulate in vivo conditions by providing oxygen and nutrients to host intestinal cells from the basal surface and permit the establishment of a low redox, high nutrient environment on the apical surface. When inoculated with 105 C. parvum (Iowa isolate) oocysts the bioreactor produced 108 oocysts per ml (20 ml extra-capillary volume) after 14 days, and was maintained for over 2 years. In vivo infectivity studies using a TCR-α-immune deficient mouse model showed that oocysts produced from the bioreactor at 6, 12 and 18 months were indistinguishable from the parent Iowa isolate used to initiate the culture. HFB produced oocysts had similar percent excystation profiles to the parent Iowa isolate.
Copyright © 2018 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Cell culture; Cryptosporidia; Cryptosporidium parvum; Hollow fiber bioreactor; Parasitology; Protozoans

Year:  2018        PMID: 34395759      PMCID: PMC8328662          DOI: 10.21769/BioProtoc.2947

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  15 in total

Review 1.  In vitro cultivation of cryptosporidium species.

Authors:  Michael J Arrowood
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

Review 2.  The Burden and Etiology of Diarrheal Illness in Developing Countries.

Authors:  Karen L Kotloff
Journal:  Pediatr Clin North Am       Date:  2017-08       Impact factor: 3.278

Review 3.  A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.

Authors:  William Checkley; A Clinton White; Devan Jaganath; Michael J Arrowood; Rachel M Chalmers; Xian-Ming Chen; Ronald Fayer; Jeffrey K Griffiths; Richard L Guerrant; Lizbeth Hedstrom; Christopher D Huston; Karen L Kotloff; Gagandeep Kang; Jan R Mead; Mark Miller; William A Petri; Jeffrey W Priest; David S Roos; Boris Striepen; R C Andrew Thompson; Honorine D Ward; Wesley A Van Voorhis; Lihua Xiao; Guan Zhu; Eric R Houpt
Journal:  Lancet Infect Dis       Date:  2014-09-29       Impact factor: 25.071

4.  Novel Bioengineered Three-Dimensional Human Intestinal Model for Long-Term Infection of Cryptosporidium parvum.

Authors:  Maria A DeCicco RePass; Ying Chen; Yinan Lin; Wenda Zhou; David L Kaplan; Honorine D Ward
Journal:  Infect Immun       Date:  2017-02-23       Impact factor: 3.441

5.  Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.

Authors:  Karen L Kotloff; James P Nataro; William C Blackwelder; Dilruba Nasrin; Tamer H Farag; Sandra Panchalingam; Yukun Wu; Samba O Sow; Dipika Sur; Robert F Breiman; Abu Sg Faruque; Anita Km Zaidi; Debasish Saha; Pedro L Alonso; Boubou Tamboura; Doh Sanogo; Uma Onwuchekwa; Byomkesh Manna; Thandavarayan Ramamurthy; Suman Kanungo; John B Ochieng; Richard Omore; Joseph O Oundo; Anowar Hossain; Sumon K Das; Shahnawaz Ahmed; Shahida Qureshi; Farheen Quadri; Richard A Adegbola; Martin Antonio; M Jahangir Hossain; Adebayo Akinsola; Inacio Mandomando; Tacilta Nhampossa; Sozinho Acácio; Kousick Biswas; Ciara E O'Reilly; Eric D Mintz; Lynette Y Berkeley; Khitam Muhsen; Halvor Sommerfelt; Roy M Robins-Browne; Myron M Levine
Journal:  Lancet       Date:  2013-05-14       Impact factor: 79.321

6.  Continuous culture of Cryptosporidium parvum using hollow fiber technology.

Authors:  Mary Morada; Sangun Lee; Leslie Gunther-Cummins; Louis M Weiss; Giovanni Widmer; Saul Tzipori; Nigel Yarlett
Journal:  Int J Parasitol       Date:  2015-09-02       Impact factor: 3.981

7.  Three-dimensional (3D) culture of adult murine colon as an in vitro model of cryptosporidiosis: Proof of concept.

Authors:  Martha Baydoun; Sadia Benamrouz Vanneste; Colette Creusy; Karine Guyot; Nausicaa Gantois; Magali Chabe; Baptiste Delaire; Anthony Mouray; Atallah Baydoun; Gerard Forzy; Vincent Chieux; Pierre Gosset; Vincent Senez; Eric Viscogliosi; Jérôme Follet; Gabriela Certad
Journal:  Sci Rep       Date:  2017-12-11       Impact factor: 4.379

8.  Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection.

Authors:  Samuel L M Arnold; Ryan Choi; Matthew A Hulverson; Deborah A Schaefer; Sumiti Vinayak; Rama S R Vidadala; Molly C McCloskey; Grant R Whitman; Wenlin Huang; Lynn K Barrett; Kayode K Ojo; Erkang Fan; Dustin J Maly; Michael W Riggs; Boris Striepen; Wesley C Van Voorhis
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

9.  Quantitative RT-PCR assay for high-throughput screening (HTS) of drugs against the growth of Cryptosporidium parvum in vitro.

Authors:  Haili Zhang; Guan Zhu
Journal:  Front Microbiol       Date:  2015-09-22       Impact factor: 5.640

10.  A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis.

Authors:  Ujjini H Manjunatha; Sumiti Vinayak; Jennifer A Zambriski; Alexander T Chao; Tracy Sy; Christian G Noble; Ghislain M C Bonamy; Ravinder R Kondreddi; Bin Zou; Peter Gedeck; Carrie F Brooks; Gillian T Herbert; Adam Sateriale; Jayesh Tandel; Susan Noh; Suresh B Lakshminarayana; Siau H Lim; Laura B Goodman; Christophe Bodenreider; Gu Feng; Lijun Zhang; Francesca Blasco; Juergen Wagner; F Joel Leong; Boris Striepen; Thierry T Diagana
Journal:  Nature       Date:  2017-05-31       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.